Your shopping cart is currently empty

Synonyms: C-75

| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $41 | In Stock | - | |
| 2 mg | $59 | 6-8 weeks | 6-8 weeks | |
| 5 mg | $98 | In Stock | - | |
| 10 mg | $165 | In Stock | - | |
| 25 mg | $332 | 6-8 weeks | 6-8 weeks | |
| 50 mg | $530 | 6-8 weeks | 6-8 weeks | |
| 100 mg | $840 | 6-8 weeks | 6-8 weeks | |
| 1 mL x 10 mM (in DMSO) | $108 | - | In Stock |
| Description | C75 is a fatty acid synthase (FASN) inhibitor (IC50 = 35 μM in PC3 cells) with cell permeability and the ability to activate CPT1A. This compound possesses antitumor activity and is commonly used in cancer-related experimental research. |
| Targets & IC50 | MCF-7 cells:27.3 μM, Fibroblast:63.2 μM, SKBR3 cells:19.8 μM, MDA-MB-231 cells:43.8 μM, MIAPaCa2 cells:21.8 μM, LNCaP cells:50 μM, PC3 cells:35 μM, HCT116 cells:46.4 μM, OVCAR-3 cells:21.9 μM |
| In vitro | Methods: The in vitro activity of C75 was validated using HeLa and CaSki cells. Cells were pretreated with 50 μM C75 for 1 hour, followed by wound healing, Transwell migration/invasion, and tube formation assays. Results: C75 significantly inhibited the migration, invasion, and lymphangiogenesis abilities of cervical cancer cells. [1] |
| In vivo | Methods: BALB/c nude mice were used to establish a cervical cancer lymph node metastasis model, with HeLa or CaSki cells inoculated into the footpad. C75 was administered via intraperitoneal injection at a dose of 10 mg/kg every other day for 2 weeks, with vehicle as control. Results: C75 treatment significantly suppressed popliteal lymph node volume and metastasis rate, and reduced lymphatic vessel density at the tumor site. [1] Methods: A 4T1 breast cancer-bearing Balb/c mouse model was used, with C75 administered via intraperitoneal injection at a dose of 10 mg/kg every 3 days for 17 consecutive days. Results: C75 monotherapy mildly inhibited tumor growth, while combination with CYH33 synergistically enhanced antitumor efficacy, increased FFA levels in tumor tissue, promoted CD8⁺ T cell infiltration, and reduced M2 macrophages. [2] |
| Synonyms | C-75 |
| Molecular Weight | 254.32 |
| Formula | C14H22O4 |
| Cas No. | 218137-86-1 |
| Smiles | CCCCCCCCC1OC(=O)C(=C)C1C(O)=O |
| Relative Density. | 1.08 g/cm3 (Predicted) |
| Storage | Store at low temperature Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 75.6 mg/mL (297.26 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 0.5% CMC-Na: 5 mg/mL (19.66 mM), Suspension. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.